The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Open accessAbstract
Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals (NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m 2 intravenous rituximab on days 1 and 8 (n=37) or NIAT alone (n=38). Median times to last follow-up were 17.0 (interquartile range, 12.5–24.0) months and 17.0 (interquartile range, 13.0–23.0) months in NIAT-rituximab and NIAT groups, respectively. Primary outcome was a combined end point of complete or partial remission of proteinuria at 6 months. At month 6, 13 (35.1%; 95% confidence interval [95% CI], 19.7 to 50.5) patients in the NIAT-rituximab group and eight (21.1%; 95% CI, 8.1 to 34.0) patients in the NIAT group achieved remission (P=0.21). Rates of antiphospholipase A2 receptor antibody (anti–PLA2R-Ab) depletion in NIAT-rituximab and NIAT groups were 14 of 25 (56%) and one of 23 (4.3%) patients at month 3 (P<0.001) and 13 of 26 (50%) and three of 25 (12%) patients at month 6 (P=0.004), respectively. Eight serious adverse events occurred in each group. During the observational phase, remission rates before change of assigned treatment were 24 of 37 (64.9%) and 13 of 38 (34.2%) patients in NIAT-rituximab and NIAT groups, respectively (P<0.01). Positive effect of rituximab on proteinuria remission occurred after 6 months. These data suggest that PLA2R-Ab levels are early markers of rituximab effect and that addition of rituximab to NIAT does not affect safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
M-Type Phospholipase A 2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy
Beck, L. H., Bonegio, R. G. B., Lambeau, G., Beck, D. M., Powell, D. W., Cummins, T. D., Klein, J. B., & Salant, D. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810457 · Cited by 2,347
Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy
Tomas, N. M., Beck, L. H., Meyer-Schwesinger, C., Seitz-Polski, B., Ma, H., Zahner, G., Dolla, G., Hoxha, E., Helmchen, U., Dabert-Gay, A.-S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409354 · Cited by 945
KDIGO Clinical Practice Guideline for Glomerulonephritis
Eckardt, K., & Kasiske, B. L. (2012) · Cited by 893
Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy
Beck, L. H., Fervenza, F. C., Beck, D. M., Bonegio, R. G. B., Malik, F. A., Erickson, S. B., Cosio, F. G., Cattran, D. C., & Salant, D. J. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111125 · Cited by 471
Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy
Schieppati, A., Mosconi, L., Perna, A., Mecca, G., Bertani, T., Garattini, S. K., & Remuzzi, G. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307083290203 · Cited by 430
Ponticelli, C., Altieri, P., Scolari, F., Passerini, P., Roccatello, D., Cesana, B., Melis, P., Valzorio, B., Sasdelli, M., Pasquali, S., et al. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v93444 · Cited by 389
Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy
Ponticelli, C. E., Zucchelli, P. C., Imbasciati, E., Cagnoli, L., Pozzi, C., Passerini, P., Grassi, C., Limido, D., Pasquali, S., Volpini, T., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198404123101503 · Cited by 380
Ruggenenti, P., Debiec, H., Ruggiero, B., Chianca, A., Pellé, T., Gaspari, F., Suardi, F., Gagliardini, E., Orisio, S., Benigni, A., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070640 · Cited by 376
Self-citationCyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial
Cattran, D. C., Appel, G. B., Hebert, L. A., Hunsicker, L. G., Pohl, M. A., Hoy, W. E., Maxwell, D. R., Kunis, C. L., & Syndrome, F. T. N. A. N. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0590041484.x · Cited by 367
Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Fervenza, F. C., Abraham, R. S., Erickson, S. B., Irazabal, M. V., Eirin, A., Specks, U., Nachman, P. H., Bergstralh, E. J., Leung, N., Cosio, F. G., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05080610 · Cited by 299
Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial
Praga, M., For the GRUPO ESPAÑOL DE ESTUDIO DE LA NEFROPATÍA MEMBRANOSA (Members of the Group listed at the end of the paper), Barrio, V., Juárez, G. F., & Luño, J. (2007) · Kidney International · doi:10.1038/sj.ki.5002215 · Cited by 280
Rituximab treatment of idiopathic membranous nephropathy
Fervenza, F. C., Cosio, F. G., Erickson, S. B., Specks, U., Herzenberg, A. M., Dillon, J. J., Leung, N., Cohen, I. M., Wochos, D. N., Bergstralh, E., et al. (2008) · Kidney International · doi:10.1038/sj.ki.5002628 · Cited by 265
Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial
Howman, A., Chapman, T. L., Langdon, M. M., Ferguson, C., Adu, D., Feehally, J., Gaskin, G. J., Jayne, D. R., O'Donoghue, D., Boulton-Jones, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61566-9 · Cited by 196
Cravedi, P., Ruggenenti, P., Sghirlanzoni, M. C., & Remuzzi, G. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01180307 · Cited by 191
Du, Y., Li, J., He, F., Lv, Y., Liu, W., Wu, P., Huang, J., Wei, S., & Gao, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104936 · Cited by 163
Treatment of idiopathic membranous nephropathy
Hofstra, J. M., Fervenza, F. C., & Wetzels, J. F. M. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.125 · Cited by 126
Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies
Ruggenenti, P. L., Mise, N., Pisoni, R., Arnoldi, F., Pezzotta, A., Perna, A., Cattaneo, D., & Remuzzi, G. (2003) · Circulation · doi:10.1161/01.cir.0000047526.08376.80 · Cited by 71
Proximal Tubules Have the Capacity to Regulate Uptake of Albumin
Wagner, M. C., Campos, S. B., Chowdhury, M., Flores, B. N., Lai, X., Myslinski, J., Pandit, S., Sandoval, R. M., Wean, S. E., Wei, Y., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014111107 · Cited by 71
Immunosuppression for Membranous Nephropathy
Chen, Y., Schieppati, A., Cai, G., Chen, X., Zamora, J., Giuliano, G. A., Braun, N., & Perna, A. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07570712 · Cited by 61
Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?
Cravedi, P., Remuzzi, G., & Ruggenenti, P. L. (2014) · Nephron Clinical Practice · doi:10.1159/000368589 · Cited by 55
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationPrimary Membranous Nephropathy
Couser, W. G. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11761116 · Cited by 690
Altered B cell signalling in autoimmunity
Rawlings, D. J., Metzler, G., Wray-Dutra, M., & Jackson, S. W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.24 · Cited by 308
Floege, J., Barbour, S. J., Cattran, D. C., Hogan, J. J., Nachman, P. H., Tang, S. C. W., Wetzels, J. F. M., Cheung, M., Wheeler, D. C., Winkelmayer, W. C., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.10.018 · Cited by 263
“The current risk stratification of patients who need treatment (>6 months of proteinuria >4 g/d) lacks specificity, as a substantial proportion of such patients may still develop spontaneous remission.(101) Models that use other cutoff points or that include the serial measurement of urinary low-molecularweight protei…”
BackgroundSelf-citationSystematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Metadata
- Authors
- Dahan, K., Debiec, H., Plaisier, E., Cachanado, M., Rousseau, A., Wakselman, L., Michel, P.-A., Mihout, F., Dussol, B., Matignon, M., Mousson, C., Simon, T., Ronco, P., & on behalf of the GEMRITUX Study Group
- Venue
- Journal of the American Society of Nephrology
- Published
- 2016-06-27
- Volume
- 28
- Issue
- 1
- Pages
- 348-358
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2470335436
- Cited by
- 439
- References
- 20
- FWCI
- 27.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.